regions. Currently, SEER covers approximately 28% of the US population. 7 Information for each patient in SEER is primarily obtained from hospital records and includes tumor characteristics, treatment, and select demographic characteristics. Given that
Search Results
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
Brooke E. Wilson, Michelle B. Nadler, Alexandra Desnoyers, and Eitan Amir
anticancer therapy before documenting an event of interest can all result in informative censoring. 3 Differential censoring between the experimental and control arms may also introduce bias, especially if it results in differences in patient characteristics
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
mortality data with results from published literature and the SEER database. Flatiron’s mortality data are estimated to have a sensitivity of 85% to 90%, specificity of 97% to 98%, and accuracy of 95% to 97%. 15 Baseline Characteristics Demographic and
Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton
2014. In addition to the traditional demographic and tumor characteristics collected by SEER, the SEER POC study collected additional variables in a sample of patients from various SEER registries. For stage IV colon cancer, these variables included the
Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero, and Adam C. Yopp
greater than 200 ng/mL, or histologic confirmation for tumors larger than 1 cm. 20 Tumor characteristics were determined by imaging studies, which had all been interpreted by radiologists at the authors’ institution, and tumor staging was performed using
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami
completion lymph node dissection (CLND) as additional therapy. Statistical Methods Clinicopathologic characteristics were recorded according to SNB (performed vs not performed) for the whole series of patients, according to SN status (positive vs negative) in
Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron
and CVD. Abbreviation: CVD, cardiovascular disease. Patient Characteristics Baseline characteristics of patients with COVID-19 are shown in Table 1 . Patients with COVID-19 and a history of cancer were older (aged 77 vs 57 years; P <.001) and more
Kate Watabayashi, Jordan Steelquist, Karen A. Overstreet, Anthony Leahy, Erin Bradshaw, Kathleen D. Gallagher, Alan J. Balch, Rebecca Lobb, Laura Lavell, Hannah Linden, Scott D. Ramsey, and Veena Shankaran
–caregiver dyads to an oncology financial navigation program. We describe the demographic and financial characteristics of enrolled subjects, the assistance provided to participants by our navigation partners, participants’ overall satisfaction with the program
Deborah K. Armstrong
patients receive chemotherapy with paclitaxel and carboplatin. In early-stage nonserous epithelial ovarian cancer, 3 cycles have been shown to be as effective as 6 Figure 1. Characteristics of ovarian cancer subtypes. Abbreviation: MP
Danielle N. Blunt, Liam Smyth, Chenthila Nagamuthu, Evgenia Gatov, Ruth Croxford, Lee Mozessohn, and Matthew C. Cheung
with >15 days from diagnosis to treatment initiation (DTI) had lower-risk characteristics and improved event-free survival (EFS) at 24 months from diagnosis compared with patients treated more urgently. Furthermore, a retrospective, observational study
